Correlation of trastuzumab treatment benefit with quantitative HER2 expression levels in HER2 positive metastatic breast cancer.

被引：0
|
作者：
Bachmeier, Beatrice
Sperinde, Jeff
Weidler, Jodi Marie
Lie, Yolanda
Chenna, Ahmed
Winslow, John
Engel, Jutta
Schubert-Fritschle, Gabriele
Sommerhoff, Christian
Petropoulos, Christos J.
Bates, Michael Patrick
Huang, Weidong
Nerlich, Andreas
机构：
[1] Univ Munich, Inst Lab Med, Munich, Germany
[2] Monogram Biosci, San Francisco, CA USA
[3] Cepheid Inc, Sunnyvale, CA USA
[4] Univ Munich, Inst Med Informat Biostat & Epidemiol, Munich, Germany
[5] Univ Hosp Munich, Inst Med Informat Biometry & Epidemiol IBE, Munich, Germany
[6] Home, Sunnyvale, CA USA
[7] Monogram Biosci Inc, LabCorp, Pleasanton, CA USA
[8] Munich Municipal Hosp, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.593
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
593
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Changes in the expression of HER2 and other genes in HER2-positive metastatic breast cancer induced by treatment with ado-trastuzumab emtansine and/or pertuzumab/trastuzumab
    Kida, K.
    Lee, J.
    Liu, H.
    Lim, B.
    Murthy, R. K.
    Sahin, A. A.
    Tripathy, D.
    Ueno, N. T.
    CANCER RESEARCH, 2019, 79 (04)
  • [32] HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer
    Lee, Hee Jin
    Seo, An Na
    Kim, Eun Joo
    Jang, Min Hye
    Suh, Koung Jin
    Ryu, Han Suk
    Kim, Yu Jung
    Kim, Jee Hyun
    Im, Seock-Ah
    Gong, Gyungyub
    Jung, Kyung Hae
    Park, In Ae
    Park, So Yeon
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 142 (06) : 755 - 766
  • [33] DURABLE REMISSIONS WITH TRASTUZUMAB TREATMENT FOR HER2 POSITIVE METASTATIC BREAST CANCER - SINGLE CENTER EXPERIENCE
    Tomasevic, Zoran
    Tomasevic, Zorica
    Neric, Dobrica
    Milosevic, Snezana
    Ivana, Bozovic-Spasojevic
    Zdravko, Zdrale
    Sarcevic, Aleksandra
    Kolarevic, Daniela
    BREAST, 2015, 24 : S42 - S42
  • [34] HER2 positive breast cancer
    Gianni, Luca
    Bianchini, Giampaolo
    CANCER RESEARCH, 2023, 83 (05)
  • [35] Single institute experience of treatment for metastatic HER2 positive breast cancer patients with trastuzumab deruxtecan
    Kojima, Yasuyuki
    Tsugawa, Koichiro
    ANNALS OF ONCOLOGY, 2021, 32 : S338 - S338
  • [36] LEVEL OF HER2/NEU GENE (HER2) AMPLIFICATION IN PRIMARY AND METASTATIC SITES IN HER2-POSITIVE METASTATIC BREAST CANCER AND RESPONSE TO TRASTUZUMAB(T)-BASED THERAPY
    Gullo, G.
    Bettio, D.
    Zuradelli, M.
    Giordano, L.
    Masci, G.
    Bareggi, C.
    Salvini, P.
    Venci, A.
    Santoro, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 101 - 101
  • [37] Prognostic significance and evolution of HER2 zero, HER2 low and HER2 positive in breast cancer after neoadjuvant treatment
    Wei, T.
    Wang, D.
    Peng, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S301 - S302
  • [38] Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer
    Wolff, Antonio C.
    Mcshane, Lisa M.
    Allison, Kimberly H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (08): : 829 - 831
  • [39] Impact of HER2 Copy Number in IHC HER2 2+/FISH Positive Breast Cancer on Outcome of Adjuvant Trastuzumab Treatment
    Borley, A.
    Mercer, T.
    Morgan, M.
    Barrett-Lee, P.
    Jasani, B.
    JOURNAL OF PATHOLOGY, 2013, 231 : 19 - 19
  • [40] Differential response of HER2 positive breast cancer based on HER2 protein expression level
    Atallah, N. M.
    Toss, M. S.
    Al Saleem, M.
    Green, A. R.
    Mongan, N. P.
    Rakha, E. A.
    JOURNAL OF PATHOLOGY, 2023, 261 : S9 - S9
12345